Designed to target solid and liquid tumors

Offers new solution for autoimmune diseases and infection diseases

Potential to treat a broad spectrum of solid tumors, lymphoma and leukemia.

Potential to treat both T cell and B cell mediated autoimmune diseases.

CNK-UT is developed from selected T cells sourced from the healthy donor

Enables industrial-scale production with high quality and low cost

Demonstrated long-term safety and efficacy in liver cancer, neuroblastoma and breast cancer patients

Demonstrated long-term safety and efficacy in treating steroid refractory graft-versus-host disease (GVHD)

Demonstrated long-term safety and efficacy in liver cancer, neuroblastoma and breast cancer patients

Demonstrated long-term safety and efficacy in treating steroid refractory graft-versus-host disease (GVHD)